NovaBay Pharmaceuticals Inc (B9P.SG)
| Previous close | 0.0655 |
| Open | 0.0645 |
| Bid | 0.0675 x N/A |
| Ask | 0.0800 x N/A |
| Day's range | 0.0645 - 0.0735 |
| 52-week range | 0.0625 - 1.0300 |
| Volume | |
| Avg. volume | 645 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
EMERYVILLE, Calif., April 22, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products. The new and enhanced programs build upon the Company’s past highly productive marketing pr
Business WireNovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
EMERYVILLE, Calif., April 19, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity. The Company must submit a plan by May 18, 2024 advising of actions it has taken or will take to regain compliance with the
- Business Wire
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
EMERYVILLE, Calif., April 17, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023. This increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the Company’s lead product, Avenova Antimicrobial Lid & Lash Solution.
